NASDAQ:ORIC Oric Pharmaceuticals Q2 2026 Earnings Results & Report $11.48 +0.17 (+1.46%) As of 11:48 AM Eastern This is a fair market value price provided by Massive. Learn more. Oric Pharmaceuticals missed analyst earnings expectations in its Q2 2026 results, released August 3, 2026. The company reported EPS of -$0.38 versus the -$0.3594 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 3, 2026TimeAfter Market ClosesConference Call4:00 PM ET Oric Pharmaceuticals EPS ResultsActual EPS-$0.38Consensus EPS -$0.3594Beat/MissMissed by -$0.0207One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersOric Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsOric Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Oric Pharmaceuticals Q2 2026 Earnings FAQ Did Oric Pharmaceuticals beat earnings estimates for Q2 2026? Oric Pharmaceuticals (NASDAQ:ORIC) reported earnings of -$0.38 per share for Q2 2026, missing the consensus estimate of -$0.3594. The report was announced on Monday, August 3, 2026. When is Oric Pharmaceuticals' next earnings date? Oric Pharmaceuticals' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Oric Pharmaceuticals on the company's earnings history page. Oric Pharmaceuticals Earnings HeadlinesDoes ORIC (ORIC) Using Off‑Balance‑Sheet Funding for ORIC‑259 Redefine Its R&D Risk Strategy?October 8, 2026 | finance.yahoo.comORIC(R) Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical DevelopmentOctober 6, 2026 | marketscreener.comMMy next big call (under $1)The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a contest offering its biggest holders a seat at dinner with the President. It's also about 97% below its peak. Because a memecoin doesn't benefit from good policy. It benefits from attention. The real winners of a pro-crypto Washington are the projects with actual businesses underneath them. Ones that get more valuable as rules get clearer, institutions get comfortable, and more money flows into the market.October 14 at 1:00 AM | Crypto 101 Media (Ad)ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical DevelopmentOctober 5, 2026 | globenewswire.comOric Pharmaceuticals (NASDAQ:ORIC) Stock Rated "Outperform" in New Coverage at Leerink PartnersOctober 5, 2026 | americanbankingnews.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comSee More Oric Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oric Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oric Pharmaceuticals and other key companies, straight to your email. Email Address About Oric PharmaceuticalsOric Pharmaceuticals (NASDAQ:ORIC) (NASDAQ: ORIC) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research is centered on mechanisms that enable tumors to resist or evade treatment, with the goal of restoring sensitivity to established cancer therapies and improving patient outcomes. Oric’s pipeline has included investigational small-molecule therapies designed to target cancer biology and treatment resistance. These programs include ORIC-533, an oral inhibitor of CD73 being studied in oncology, and ORIC-944, an oral allosteric inhibitor of EED, a component of the polycomb repressive complex 2. The company has also developed ORIC-114, a brain-penetrant investigational inhibitor directed at selected EGFR and HER2 alterations. Founded in 2014 and headquartered in South San Francisco, California, Oric Pharmaceuticals conducts research and clinical development activities through collaborations with academic institutions, clinical investigators and other biotechnology or pharmaceutical organizations. Its programs are intended for patients with solid tumors and hematologic malignancies, although the availability and status of specific candidates may change as clinical studies progress.View Oric Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
